Empagliflozin 10 MG: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Empagliflozin 10 MG appears in the FDA drug-label database. Marketed as JARDIANCE.
- Drug class
- Sodium-Glucose Cotransporter 2 Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Sodium-Glucose Transporter 2 Inhibitors (as stated on the FDA label)
FDA-approved use
JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. ( 1 ) To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2 ( 1 ) Limitations of Use JARDIANCE is not recommended in patients with type 1 diabetes mellitus. It may increase the r…
FDA recalls / enforcement
| Reason (FDA) | Classification | Status | Initiated |
|---|---|---|---|
| Cross Contamination With Other Products: — Boehringer Ingelheim Pharmaceuticals, Inc. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2018-09-04 |
| Labeling: Label Mix-up — Boehringer Ingelheim Pharmaceuticals, Inc. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2023-03-09 |
| CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Cardinal Health Inc. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2021-03-15 |
| CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. — CARDINAL HEALTHCARE | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2022-01-26 |
Phase breakdown
Conditions being studied
Recruiting trials involving Empagliflozin 10 MG
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
- EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
- Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
- Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
- Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
- Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
- Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
- Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
- Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
- Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
- Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
- SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
- Safety and Efficacy of Empagliflozin in Hemodialysis
- The EMPA-FIT Study
- The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Common questions
Is Empagliflozin 10 MG FDA-approved?
Yes, marketed as JARDIANCE.
How many recruiting trials involve Empagliflozin 10 MG?
15 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.